Current and evolving therapies for metastatic pancreatic cancer: Are we stuck with cytotoxic chemotherapy?

Journal of Oncology Practice

Volumn 12, Issue 9, 2016, Pages 797-805

  Varadhachary, Gauri R ^a   Wolff, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; CYTOTOXIN;

CANCER CHEMOTHERAPY; CYTOTOXICITY; HUMAN; INTRACELLULAR SPACE; METABOLIC REGULATION; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT SELECTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; PANCREATIC NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; HUMANS; PANCREATIC NEOPLASMS;

EID: 84987657582     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.015586     Document Type: Review

References (47)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
2. Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin 63:318-348, 2013
3. Burris HA, III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
4. Cascinu S, Berardi R, Labianca R, et al: Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol 9:39-44, 2008
5. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006
6. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010
7. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 12:256-262, 2011
8. Catenacci DV, Junttila MR, Karrison T, et al: Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol 33:4284-4292, 2015
9. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
10. Heinemann V, Boeck S, Hinke A, et al: Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008
11. Sultana A, Smith CT, Cunningham D, et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607-2615, 2007
12. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
13. Gunturu KS, Yao X, Cong X, et al: FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med Oncol 30:361, 2013
14. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
15. Sohal DP, Mangu PB, Khorana AA, et al: Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol 34:2784-2796, 2016
16. Oettle H, Riess H, Stieler JM, et al: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol 32: 2423-2429, 2014
17. Zaniboni A, Aitini E, Barni S, et al: FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: A GISCAD multicenter phase II study. Cancer Chemother Pharmacol 69:1641-1645, 2012
18. Yoo C, Hwang JY, Kim JE, et al: A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabinerefractory advanced pancreatic cancer. Br J Cancer 101:1658-1663, 2009
19. Wang-Gillam A, Li CP, Bodoky G, et al: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 387: 545-557, 2016
20. Infante JR, Keedy VL, Jones SF, et al: Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70:699-705, 2012
21. Herman JM, Hoffman JP, Thayer SP, et al: Management of the primary tumor and limited metastases in patients with metastatic pancreatic cancer. J Natl Compr Canc Netw 13:e29-e36, 2015
22. Mettu NB, Abbruzzese JL: Clinical insights into the biology and treatment of pancreatic cancer. J Oncol Pract 12:17-23, 2016
23. Bailey P, Chang DK, Nones K, et al: Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47-52, 2016
24. Biankin AV, Maitra A: Subtyping pancreatic cancer. Cancer Cell 28:411-413, 2015
25. Becker AE, Hernandez YG, Frucht H, et al: Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J Gastroenterol 20:11182-11198, 2014
26. Peng G, Chun-Jen Lin C, Mo W, et al: Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014
27. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33: 244-250, 2015
28. Ma Y, Hwang RF, Logsdon CD, et al: Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 73:3927-3937, 2013
29. Bullock AJ, Hingorani SR, Wu XW, et al: Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay. J Clin Oncol 34, 2016 (abstr 4104)
30. O'Reilly EM, Mahalingam D, Roach JM, et al: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results. J Clin Oncol 34, 2016 (abstr 4117)
31. Massó-Vallés D, Jauset T, Serrano E, et al: Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res 75: 1675-1681, 2015
32. Tempero MA, Coussens LM, Fong L, et al: A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). J Clin Oncol 34, 2016 (suppl 4S; abstr TPS2601)
33. Overman MJ, Lopez CD, Benson AB, et al: A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). J Clin Oncol 34, 2016 (abstr 4130)
34. Schwartz GG, Eads D, Naczki C, et al: 19-nor-1 α,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 7:430-436, 2008
35. Byrne KT, Vonderheide RH: CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 15:2719-2732, 2016
36. Mellman I, Hubbard-Lucey VM, Tontonoz MJ, et al: De-risking immunotherapy: Report of a consensus workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol Res 4:279-288, 2016
37. Nywening TM, Wang-Gillam A, Sanford DE, et al: Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651-662, 2016
38. O'Reilly EM, Walker C, Clark J, et al: JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy. J Clin Oncol 33, 2015 (abstr TPS4146)
39. Bayne LJ, Beatty GL, Jhala N, et al: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822-835, 2012
40. Le DT, Wang-Gillam A, Picozzi V, et al: Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325-1333, 2015
41. Soares KC, Rucki AA, Wu AA, et al: PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 38:1-11, 2015
42. Royal RE, Levy C, Turner K, et al: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828-833, 2010
43. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
44. Sockolosky JT, Dougan M, Ingram JR, et al: Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA 113: E2646-E2654, 2016
45. Chaudhuri L, Srivastava RK, Kos F, et al: Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD81 T cells. Cancer Immunol Immunother 65:869-874, 2016
46. Viale A, Pettazzoni P, Lyssiotis CA, et al: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514:628-632, 2014
47. Philip PA, Mooney M, Jaffe D, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660-5669, 2009